Martens, Pieter
Ferreira, João Pedro
Vincent, John
Abreu, Paula
Busselen, Martijn
Mullens, Wilfried
Tang, Wilson W. H.
Böhm, Michael
Pitt, Bertram
Zannad, Faiez
Rossignol, Patrick
Article History
Received: 1 December 2020
Accepted: 1 April 2021
First Online: 23 April 2021
Declarations
:
: Upon request, and subject to certain criteria, conditions and exceptions (see ExternalRef removed for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (a) for indications that have been approved in the US and/or EU or (b) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.